文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

MDM2调控HIF信号导致肥厚型心肌病微血管功能障碍

MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy.
PubMed 文献 · Circulation · 2023-10-27

该研究在携带Mybpc3或Myh6突变的HCM小鼠模型中,用多模态影像追踪微血管功能障碍的时间过程,并通过分子实验和遗传/药物干预验证机制。发现微血管功能障碍源于出生后早期毛细血管生长减少,可早于心肌肥厚出现;MDM2动态调控HIF1α和HIF2α/EPAS1蛋白稳定性,导致HIF失衡和促血管生成基因表达降低;降低MDM2可恢复HIF水平并预防微血管功能障碍。

要点

  • HCM中微血管功能障碍由毛细血管生长减少所致,可独立于心肌肥厚发生。
  • 肉瘤基因突变诱导心肌细胞MDM2信号,动态调控HIF1α和HIF2α/EPAS1蛋白稳定性。
  • 遗传或药物降低MDM2可恢复HIF水平并预防两种HCM模型的微血管功能障碍。

核心结论

  • 肉瘤基因突变在疾病最早期诱导心肌细胞MDM2信号,导致心肌微环境长期改变。

研究设计与样本

  • 研究使用携带Mybpc3或Myh6突变的HCM小鼠模型,采用多模态影像追踪微血管功能障碍的时间过程。
  • 研究进行互补的分子方法评估蛋白数量、相互作用和翻译后修饰,并用遗传和药理方法在体内操纵选定分子通路验证机制。

主要发现

  • HCM模型中的微血管功能障碍继发于出生后早期心肌毛细血管生长减少,且可发生在心肌肥厚之前。
  • E3泛素蛋白连接酶MDM2通过经典和非经典机制动态调控HIF1α和HIF2α/EPAS1的蛋白稳定性。
  • 由此产生的HIF失衡导致心肌毛细血管生长的关键时期促血管生成基因表达降低。
  • 通过遗传或药理方法降低MDM2蛋白水平可正常化HIF蛋白水平,并预防两种HCM模型的微血管功能障碍。

临床怎么用

  • MDM2-HIF通路可能成为HCM早期微血管功能障碍的干预靶点,但需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Microvasculature dysfunction is a common finding in pathologic remodeling of the heart and is thought to play an important role in the pathogenesis of hypertrophic cardiomyopathy (HCM), a disease caused by sarcomere gene mutations. We hypothesized that microvascular dysfunction in HCM was secondary to abnormal microvascular growth and could occur independent of ventricular hypertrophy. METHODS: We used multimodality imaging methods to track the temporality of microvascular dysfunction in HCM mouse models harboring mutations in the sarcomere genes Mybpc3 (cardiac myosin binding protein C3) or Myh6 (myosin heavy chain 6). We performed complementary molecular methods to assess protein quantity, interactions, and post-translational modifications to identify mechanisms regulating this response. We manipulated select molecular pathways in vivo using both genetic and pharmacological methods to validate these mechanisms. RESULTS: We found that microvascular dysfunction in our HCM models occurred secondary to reduced myocardial capillary growth during the early postnatal time period and could occur before the onset of myocardial hypertrophy. We discovered that the E3 ubiquitin protein ligase MDM2 (murine double minute 2) dynamically regulates the protein stability of both HIF1α (hypoxia-inducible factor 1 alpha) and HIF2α (hypoxia-inducible factor 2 alpha)/EPAS1 (endothelial PAS domain protein 1) through canonical and noncanonical mechanisms. The resulting HIF imbalance leads to reduced proangiogenic gene expression during a key period of myocardial capillary growth. Reducing MDM2 protein levels by genetic or pharmacological methods normalized HIF protein levels and prevented the development of microvascular dysfunction in both HCM models. CONCLUSIONS: Our results show that sarcomere mutations induce cardiomyocyte MDM2 signaling during the earliest stages of disease, and this leads to long-term changes in the myocardial microenvironment.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Shridhar P, Glennon MS, Pal S, et al. MDM2 Regulation of HIF Signaling Causes Microvascular Dysfunction in Hypertrophic Cardiomyopathy. Circulation. 2023. PMID: 37886847. doi:10.1161/CIRCULATIONAHA.123.064332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。